10 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

4 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Dec 2027

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028202920302031 2032 2033 203420352036203720382039204020412042204320442045

notable patents all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms US 10,150,999

The most cited patent in this portfolio, cited by 32 later US patents, top 10% of utility patents granted in 2018 in our data. Protection runs to 2031.

Ends Nov 2031 · High confidence Also notable

Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma US 10,255,410

The largest patent family in this portfolio, 5 related applications, renewed at 2 of 3 maintenance windows. Protection runs to 2033.

Ends Jan 2033 · High confidence Also notable

Methods for Measuring Carcinoembryonic Antigen US 10,444,239

Granted 2019. Computed term ends 2033.

Ends Nov 2033 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 15, 2027
The maintenance fee for Methods for Measuring Carcinoembryonic Antigen (US 10,444,239) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma	3 in force	to Mar 2033
Methods for Measuring Carcinoembryonic Antigen	2 in force	to Mar 2034
Methods and Compositions Involving MIR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	2 in force	to Sep 2032
Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	2 in force	to Nov 2031
Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions	1 in force	to Dec 2027

Patents held now

Soonest term end first.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 11,143,657	Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions In force Term ends Dec 1, 2027 · High confidence	In force	Term ends Dec 1, 2027	High confidence
US 10,150,999	Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms In force Term ends Nov 17, 2031 · High confidence	In force	Term ends Nov 17, 2031	High confidence
US 11,118,231	Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms In force Term ends Nov 17, 2031 · High confidence	In force	Term ends Nov 17, 2031	High confidence
US 9,644,241	Methods and Compositions Involving MIR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease In force Term ends Sep 13, 2032 · High confidence	In force	Term ends Sep 13, 2032	High confidence
US 10,655,184	Methods and Compositions Involving MIR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease In force Term ends Sep 13, 2032 · High confidence	In force	Term ends Sep 13, 2032	High confidence
US 10,255,410	Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma In force Term ends Jan 23, 2033 · High confidence	In force	Term ends Jan 23, 2033	High confidence
US 12,205,676	Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma In force Term ends Jan 23, 2033 · High confidence	In force	Term ends Jan 23, 2033	High confidence
US 10,131,942	Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma In force Term ends Mar 19, 2033 · High confidence	In force	Term ends Mar 19, 2033	High confidence
US 10,444,239	Methods for Measuring Carcinoembryonic Antigen In force Term ends Nov 27, 2033 · Medium confidence	In force	Term ends Nov 27, 2033	Medium confidence
US 9,341,628	Methods for Measuring Carcinoembryonic Antigen In force Term ends Mar 23, 2034 · High confidence	In force	Term ends Mar 23, 2034	High confidence

Also on record, not counted in the 10: 1 patent ended · 2 applications pending · 16 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Interpace Diagnostics Corporation